From the ‡GSK Vaccines, Siena, Italy.
From the ‡GSK Vaccines, Siena, Italy
Mol Cell Proteomics. 2018 Feb;17(2):205-215. doi: 10.1074/mcp.RA117.000045. Epub 2017 Dec 4.
Despite high vaccination coverage world-wide, whooping cough, a highly contagious disease caused by is recently increasing in occurrence suggesting that novel vaccine formulations targeted at the prevention of colonization and transmission should be investigated. To identify new candidates for inclusion in the acellular formulation, we used spontaneously released outer membrane vesicles (OMV) as a potential source of key adhesins. The enrichment of Bvg+ OMV with adhesins and the ability of anti-OMV serum to inhibit the adhesion of to lung epithelial cells were demonstrated. We employed a proteomic approach to identify the differentially expressed proteins in OMV purified from bacteria in the Bvg+ and Bvg- virulence phases, thus comparing the outer membrane protein pattern of this pathogen in its virulent or avirulent state. Six of the most abundant outer membrane proteins were selected as candidates to be evaluated for their adhesive properties and vaccine potential. We generated strains singularly expressing the selected proteins and assessed their ability to adhere to lung epithelial cells Four out of the selected proteins conferred adhesive ability to Three of the candidates were specifically detected by anti-OMV mouse serum suggesting that these proteins are immunogenic antigens able to elicit an antibody response when displayed on the OMV. Anti-OMV serum was able to inhibit only BrkA-expressing adhesion to lung epithelial cells. Finally, stand-alone immunization of mice with recombinant BrkA resulted in significant protection against infection of the lower respiratory tract after challenge with Taken together, these data support the inclusion of BrkA and possibly further adhesins to the current acellular pertussis vaccines to improve the impact of vaccination on the bacterial clearance.
尽管全球疫苗接种率很高,但由 引起的高度传染性疾病百日咳最近的发病率正在上升,这表明应该研究针对定植和传播预防的新型疫苗制剂。为了确定新的候选疫苗纳入无细胞制剂,我们使用自发释放的外膜囊泡 (OMV) 作为关键粘附素的潜在来源。已经证明了粘附素在 Bvg+ OMV 中的富集以及抗 OMV 血清抑制 对肺上皮细胞的粘附的能力。我们采用蛋白质组学方法来鉴定在 Bvg+和 Bvg-毒力阶段从细菌中纯化的 OMV 中差异表达的蛋白质,从而比较该病原体在其毒力或非毒力状态下的外膜蛋白模式。选择了六个最丰富的外膜蛋白作为候选蛋白,以评估它们的粘附特性和疫苗潜力。我们生成了单独表达所选蛋白的 菌株,并评估了它们粘附肺上皮细胞的能力。四种选定的蛋白赋予了 粘附能力。三种候选蛋白被抗 OMV 鼠血清特异性检测到,这表明这些蛋白是免疫原性抗原,当在 OMV 上展示时能够引发抗体反应。抗 OMV 血清仅能抑制 BrkA 表达的 对肺上皮细胞的粘附。最后,单独用重组 BrkA 免疫小鼠可显著防止在挑战后感染下呼吸道 总而言之,这些数据支持将 BrkA 和可能进一步的粘附素纳入当前的无细胞百日咳疫苗中,以提高疫苗对细菌清除的影响。